A patent review of topoisomerase I inhibitors (2016–present)

References

• JB L, Champoux JJ. Human DNA topoisomerase I: relaxation, roles, and damage control. Chromosoma. 2005;114:75–85.
   PubMed Web of Science ®Google Scholar
• Martino E, Della Volpe S, Terribile E, et al. The long story of camptothecin: from traditional medicine to drugs. Bioorg Med Chem Lett. 2017;27(4):701–707.
   PubMed Web of Science ®Google Scholar
• Pommier Y. DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev. 2009;109:2894–2902.
   PubMed Web of Science ®Google Scholar
• Reguera RM, Redondo CM, Gutierrez de Prado R, et al. DNA topoisomerase I from parasitic protozoa: a potential target for chemotherapy. Biochim Biophys Acta. 2006;1759:117–131.
   PubMedGoogle Scholar
• Tse-Dinh YC. Targeting bacterial topoisomerase I to meet the challenge of finding new antibiotics. Future Med Chem. 2015;7:459–471.
   PubMed Web of Science ®Google Scholar
• Pommier Y. DNA topoisomerases and cancer. New York: Springer; 2012.
   Google Scholar
• Wang JC. Interaction between DNA and an Escherichia coli protein ω. J Mol Biol. 1971;55:523–533.
   PubMed Web of Science ®Google Scholar
• Champoux JJ. DNA topoisomerases: structure, function, and mechanism. Annu Rev Biochem. 2001;70:369–413.
   PubMed Web of Science ®Google Scholar
• Pommier Y, Leo E, Zhang HL, et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem Biol. 2010;17:421–433.
   PubMed Web of Science ®Google Scholar
• Barros FWA, Bezerra DP, Ferreira PMP, et al. Inhibition of DNA topoisomerase I activity and induction of apoptosis by thiazacridine derivatives. Toxicol Appl Pharmacol. 2013;268:37–46.
   PubMed Web of Science ®Google Scholar
• Kim S-H, Lee E, Baek KH, et al. Chalcones, inhibitors for topoisomerase I and cathepsin B and L, as potential anti-cancer agents. Bioorg Med Chem Lett. 2013;23:3320–3324.
   PubMed Web of Science ®Google Scholar
• Forterre P, Gribaldo S, Gadelle D, et al. Origin and evolution of DNA topoisomerases. Biochimie. 2007;89:427. (b) Schoeffler AJ, Berger JM. DNA topoisomerases: harnessing and constraining energy to govern chromosome topology. Q Rev Biophys 2008, 41, 41–101
   PubMed Web of Science ®Google Scholar
• Thomas A, Pommier Y. Targeting Topoisomerase I in the era of precision medicine. Clin Cancer Res. 2019;25:6581–6589.
   PubMed Web of Science ®Google Scholar
• Staker BL, Feese MD, Cushman M, et al. Structures of three classes of anticancer agents bound to the human Topoisomerase I−DNA covalent complex. Journal of Medicinal Chemistry. 2005;48(7):2336–2345.
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res. 1988;48:1722–1726.
   PubMed Web of Science ®Google Scholar
• Hsiang YH, Hertzberg R, Hecht S, et al. Camptothecin induces protein‐linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem. 1985;27:14873–14878.
   Google Scholar
• Postma C, Koopman M, Buffart TE, et al. DNA copy number profiles of primary tumors as predictors of response to chemotherapy in advanced colorectal cancer. Ann Oncol. 2009;20:1048–1056.
   PubMed Web of Science ®Google Scholar
• Hatefi A, Amsden B. Camptothecin delivery methods. Pharm Res. 2002;19:1389–1399.
   PubMed Web of Science ®Google Scholar
• Li F, Jiang T, Li Q, et al. Camptothecin (CPT) and its derivatives are known to target topoisomerase I (TopI) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer? Am. J. Cancer Res.2017;7:2350–2394. .
   PubMed Web of Science ®Google Scholar
• Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat Rev Cancer. 2006;6:789–802.
   PubMed Web of Science ®Google Scholar
• Ikeguchi M, Arai Y, Maeta Y, et al. Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer. Surg Today. 2011;41:1196–1199.
   PubMed Web of Science ®Google Scholar
• Wethington SL, Wright JD, Herzog TJ. Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma. Expert Rev Anticancer Ther. 2008;8:819–831.
   PubMed Web of Science ®Google Scholar
• Fu P, Zhuang Y, Wang Y, et al. New indolocarbazoles from a mutant strain of the marine-derived actinomycete Streptomyces fradiae 007M135. Org Lett. 2012;14:6194–6197.
   PubMed Web of Science ®Google Scholar
• Sánchez C, Méndez C, Salas JA. Indolocarbazole natural products: occurrence, biosynthesis, and biological activity. Nat Prod Rep. 2006;23:1007–1045.
   PubMed Web of Science ®Google Scholar
• Omura S, Iwai Y, Hirano A, et al. A new alkaloid AM-2282 OF Streptomyces origin. Taxonomy, fermentation, isolation and preliminary characterization. J Antibiot. 1977;30:275–282.
   PubMed Web of Science ®Google Scholar
• Saif MW, Sellers S, Diasio RB, et al. A phase I dose‐escalation study of edotecarin (J‐107088) combined with infusional 5‐fluorouracil and leucovorin in patients with advanced/metastatic solid tumors. Anti‐Cancer Drugs 2010;21:716–723.
   PubMed Web of Science ®Google Scholar
• Cagir A, Jones SH, Gao R, et al. A naturally occurring human DNA topoisomerase I poison. J Am Chem Soc. 2003;125:13628–13629.
   PubMed Web of Science ®Google Scholar
• Iwasaki H, Inafuku M, Taira N, et al. Tumor‐selective cytotoxicity of nitidine results from its rapid accumulation into mitochondria. BioMed. Res. Intl.. 2017;2017:1–10.
   Web of Science ®Google Scholar
• Ivanova B, Spiteller M. Substituted benzo[i]phenanthridines as promising topoisomerase-I non-camptothecin targeting agents: an experimental and theoretical study. Medicinal Chemistry Research. 2013;22(11):5204–5217.
   Web of Science ®Google Scholar
• Feng W, Satyanarayana M, Tsai Y-C, et al. LaVoie EJ.12-Substituted 2,3-dimethoxy-8,9-methylenedioxybenzo[i]phenanthridines as novel topoisomerase I-targeting antitumor agents. Bioorg Med Chem. 2009;17:2877–2885.
   PubMed Web of Science ®Google Scholar
• Clark RL, Deane FM, Anthony NG, et al. Exploring DNA topoisomerase I inhibition by the benzo[c]phenanthridines fagaronine and ethoxidine using steered molecular dynamics. Bioorg Med Chem. 2007;15:4741–4752.
   PubMed Web of Science ®Google Scholar
• Fang SD, Wang LK, Hecht SM. Inhibitors of DNA topoisomerase I isolated from the roots of zanthoxylum nitidum. The Journal of Organic Chemistry. 1993;58(19):5025–5027.
   Web of Science ®Google Scholar
• Arthur HR, Hui WH, Ng YL. An examination of the rutaceae of Hong Kong. Part III. The alkaloid, avicine, from Zanthoxylum avicennae. J Chem Soc. 1959;4007–4009.
   Web of Science ®Google Scholar
• Castelli S, Kathar P, Vassallo O, et al. Anti-cancer agents. Med Chem. 2013;13:356–363.
   Google Scholar
• Marco E, Laine W, Tardy C, et al. Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure‐activity relationships. J Med Chem. 2005;48:3807.
   Web of Science ®Google Scholar
• Facompre M, Tardy C, Bal-Mahieu C, et al. Lamellarin D: a novel potent inhibitor of topoisomerase I. Cancer Res. 2003;63:7392–7399.
   PubMed Web of Science ®Google Scholar
• Cinelli MA, Morrell AE, Dexheimer TS, et al. The structure-activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding mode. Bioorg Med Chem. 2010;18:5535–5552.
   PubMed Web of Science ®Google Scholar
• Kiselev E, Sooryakumar D, Agama K, et al. Optimization of the lactam side chain of 7‐azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells. J Med Chem. 2014;57:1289–1298.
   PubMed Web of Science ®Google Scholar
• Beck DE, Reddy PVN, Lv W, et al. Investigation of the structure‐activity relationships of aza‐A‐ring indenoisoquinoline topoisomerase I poisons. J Med Chem. 2016;59:3840–3853.
   PubMed Web of Science ®Google Scholar
• Cushman M, Cheng L. Stereoselective oxidation by thionyl chloride leading to the indeno[1,2‐c]isoquinoline system. J Org Chem. 1978;43:3781–3783.
   Web of Science ®Google Scholar
• Beck DE, Agama K, Marchand C, et al. Synthesis and biological evaluation of new carbohydrate substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776). J Med Chem. 2014;57:1495–1512.
   PubMed Web of Science ®Google Scholar
• Burton JH, Mazcko C, Leblanc A, et al. NCI comparative oncology program testing of non-camptothecin indenoisoquinoline topoisomerase i inhibitors in naturally occurring canine lymphoma. Clin Cancer Res. 2018;24:5830–5840.
   PubMed Web of Science ®Google Scholar
• O’Sullivan Coyne GH, Kummar S, Meehan RS, et al. Phase I study of indenoisoquinolines LMP776 in adults with relapsed solid tumors and lymphomas. Journal of Clinical Oncology. 2017;35(15_suppl):2558.
   PubMedGoogle Scholar
• Ruchelman AL, Singh SK, Wu X, et al. Diaza- and triazachrysenes: potent topoisomerase-targeting agents with exceptional antitumor activity against the human tumor xenograft, MDA-MB-435. Bioorg. Med Chem Lett. 2002;12:3333–3336.
   PubMed Web of Science ®Google Scholar
• Kiselev E, Dexheimer TS, Pommier Y, et al. Synthesis and Evaluation of Dibenzo[c,h][1,6]naphthyridines as Topoisomerase I inhibitors and potential anticancer agents. J Med Chem. 2010;53:8716–8726.
   PubMed Web of Science ®Google Scholar
• Alonso C, Fuertes M, Gonzalez M, et al. Synthesis and biological evaluation of 1,5-naphthyridines as topoisomerase I inhibitors. A new family of antiproliferative agents. Curr Top Med Chem. 2014;14:2722–2728.
   PubMed Web of Science ®Google Scholar
• Alonso C, Fuertes M, Gonzalez M, et al. Synthesis and biological evaluation of indeno[1,5]naphthyridines as topoisomerase I (TopI) inhibitors with antiproliferative activity. European Journal of Medicinal Chemistry. 2016;115: 179–190.
   PubMed Web of Science ®Google Scholar
• Tejeria A, Perez-Pertejo Y, Reguera RM, et al. Substituted 1,5-naphthyridines derivatives as novel Antileishmanial agents. Synthesis and biological evaluation. Eur J Med Chem. 2018;152:137–147.
   PubMed Web of Science ®Google Scholar
• Tejeria A, Perez-Pertejo Y, Reguera RM, et al. Antileishmanial effect of new indeno-1,5-naphthyridines, selective inhibitors of Leishmania infantum type IB DNA topoisomerase. Eur J Med Chem. 2016;124:740–749.
   PubMed Web of Science ®Google Scholar
• Andersen MB, Tesauro C, Gonzalez M, et al. Advantages of an optical nanosensor system for mechanistic analysis of a novel topoisomerase I targeting drug: a case story. Nanoscale. 2017;9:1886–1895.
   PubMed Web of Science ®Google Scholar
• Martín-Encinas E, Rubiales G, Knudsen BR, et al. Straightforward synthesis and biological evaluation as topoisomerase I inhibitors and antiproliferative agents of hybrid chromeno[4,3-b][1,5]naphthyridines and chromeno[4,3-b][1,5]naphthyridin-6-ones. Eur J Med Chem. 2019;178:752–766.
   PubMed Web of Science ®Google Scholar
• Martín-Encinas E, Selas A, Rubiales G, et al. Synthesis of novel hybrid quinolino[4,3-b][1,5]naphthyridines and quinolino[4,3-b][1,5]naphthyridin-6(5H)-one derivatives and biological evaluation as topoisomerase I inhibitors and antiproliferatives. Eur J Med Chem. 2020;195:112292.
   PubMed Web of Science ®Google Scholar
• Alonso C, Fuertes M, Martín-Encinas E, et al. Novel topoisomerase I inhibitors. Syntheses and biological evaluation of phosphorus substituted quinoline derivates with antiproliferative activity. Eur J Med Chem. 2018;149:225–237.
   PubMed Web of Science ®Google Scholar
• Tejeria A, Perez-Pertejo Y, Reguera RM, et al. Antileishmanial activity of new hybrid tetrahydroquinoline derivatives with phosphorus substituents. Eur J Med Chem. 2019;162:18–31.
   PubMed Web of Science ®Google Scholar
• Skok Z, Zidar N, Kikelj D, et al. Dual inhibitors of human DNA topoisomerase II and other cancer-related targets. J Med Chem. 2020;63:884–904.
   PubMed Web of Science ®Google Scholar
• Liang X, Wu Q, Luan S, et al. A comprehensive review of topoisomerase inhibitors as anticancer agents in the past decade. Eur J Med Chem. 2019;171:129–168.
   PubMed Web of Science ®Google Scholar
• Hevenern KE, Verstak TA, Lutat KE, et al. Recent developments in topoisomerase-targeted cancer chemotherapy. Acta Pharm Sin B. 2018;8:844–861.
   PubMed Web of Science ®Google Scholar
• Capranico G, Marinello J, Chillemi G. Type I DNA Topoisomerases. J Med Chem. 2017;60:2169–2192.
   PubMed Web of Science ®Google Scholar
• Kathiravan MK, Kale AN, Nilewar S. Discovery and development of topoisomerase inhibitors as anticancer agents. Mini-Rev Med Chem. 2016;16:1229.
   Web of Science ®Google Scholar
• D’Annessa I, Castelli S, Desideri A. Topoisomerase 1B as a target against Leishmaniasis. Mini-Rev Med Chem. 2015;15:203–210.
   PubMed Web of Science ®Google Scholar
• Khadka DB, Cho W-J. Topoisomerase inhibitors as anticancer agents: a patent update. Expert Opin Ther Pat. 2013;23:1033–1056.
   PubMed Web of Science ®Google Scholar
• Singh A, Kaur N, Singh G, et al. Topoisomerase I and II inhibitors: a patent review. Recent Pat. Anti-Cancer Drug Discov.. 2016;11:401–423.
   PubMed Web of Science ®Google Scholar
• Wang C, Shao C, Wang M, et al. Application of phenol derivatives in preparation of topoisomerase I inhibitor. Faming Zhuanli Shenqing CN 108938605, 2018.
   Google Scholar
• Wang C, Shao C, Wang M, et al. Marine fungus separated from gorgonian and its application in preparing topoisomerase I inhibitor. Faming Zhuanli Shenqing CN 108929857, 2018.
   Google Scholar
• Wang C, Shao C, Xin L, et al. Application of flavonoid compound in preparation of topoisomerase I inhibitor. Faming Zhuanli Shenqing CN 108926553, 2018.
   Google Scholar
• Nishizawa M, Emura M, Kan Y, et al. Macrocarpals: HIV-RTase inhibitors of Eucalyptus globulus. Tetrahedron Lett. 1992;33:2983–2986.
   Web of Science ®Google Scholar
• Shou Q, Smith JE, Mon H, et al. Rhodomyrtals A-D, four unusual phloroglucinol-sesquiterpene adducts from Rhodomyrtus psidioides. RSC Adv. 2014;4:13514–13517.
   Web of Science ®Google Scholar
• S-P Y, X-W Z, Ai J, et al. Potent HGF/c-Met axis inhibitors from Eucalyptus globulus: the coupling of phloroglucinol and sesquiterpenoid is essential for the activity. J Med Chem. 2012;55:8183–8187.
   PubMed Web of Science ®Google Scholar
• Liu N, Ni W, Jin L, et al. Novel topoisomerase I inhibitor, and its pharmaceutical composition, preparation method and application in preparing drugs for treating cancer and complications and preparing functional health-care product. Faming Zhuanli Shenqing CN 107986951, 2018.
   Google Scholar
• Tang Y, Duan J, Le S Quinoid chalcone-C-glycoside dimer compound having antitumor and antiinflammatory activity. PCT Int. Appl. WO 2017219510, 2017.
   Google Scholar
• Tang Y, Yue S, Duan J, et al. Quinoid chalcone-C-glycoside dimer compound with antitumor and antiinflammatory activity. Faming Zhuanli Shenqing CN 106083788, 2016.
   Google Scholar
• Tang Y, Duan J, Le S Quinoid chalcone and flavonol conjugate having antitumor activity and antiinflammatory activity, preparation method therefor, and application thereof. PCT Int. Appl. WO 2017219509, 2017.
   Google Scholar
• Tang Y, Yue S, Duan J, et al. Preparation method of quinone chalcone and flavonol conjugate with antitumor and antiinflammatory activity, and application thereof. Faming Zhuanli Shenqing CN 106146581, 2016.
   Google Scholar
• Guo M, Chen G, Tian Y, et al. Method for fast screening topoisomerase I inhibitor from natural product. Faming Zhuanli Shenqing CN 105717250, 2016.
   Google Scholar
• Weng J, Kong Y, Pang K, et al. Preparation method of adamantane formamido ethyl formate as antitumor agents. Faming Zhuanli Shenqing CN 110423216, 2019.
   Google Scholar
• Weng J, Kong Y, Wen Y, et al. 2-substituted-phenyl-3-(1-adamantane formamido)-4-thiazoline ketone compounds and its synthetic method and application. Faming Zhuanli Shenqing CN 110407766, 2019.
   Google Scholar
• Weng J, Wen Y, Kong Y, et al. Adamantane formamide compound and its preparation method and application. Faming Zhuanli Shenqing CN 110790677, 2019.
   Google Scholar
• Weng J, Ye F, Zhu Y, et al. Preparation of stilbene analogues with thiazole structure as antitumor agents. Faming Zhuanli Shenqing CN 110407767, 2019.
   Google Scholar
• Yuan J, Novel GG I-type topoisomerase inhibitor. Faming Zhuanli Shenqing CN 110845389, 2020.
   Google Scholar
• Wang J, Yun D, Yao J, et al. Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds Jiabing. Eur J Med Chem. 2018;144:493–503.
   PubMed Web of Science ®Google Scholar
• Liu J, Geng G, Liang G, et al. A novel topoisomerase I inhibitor DIA-001 induces DNA damage mediated cell cycle arrest and apoptosis in cancer cell. Ann Transl Med. 2020;8:89–97.
   PubMed Web of Science ®Google Scholar
• Talukdar A, Das BB, Kundu B, et al. Bicycle topoisomerase I inhibiting compounds, process for preparation and use thereof. Indian Pat. Appl. IN 201811020003, PCT Int. Appl. WO2019229765A1, 2019.
   Google Scholar
• Kundu B, Das SK, Chowdhuri SP, et al. Discovery and mechanistic study of tailor-made quinoline derivatives as Topoisomerase 1 poison with potent anticancer activity. J Med Chem. 2019;62:3428–3446.
   PubMed Web of Science ®Google Scholar
• Kerns RJ, Towle T, Hiasa H Quinolone-based compounds with anticancer activity. PCT Int. Appl. WO 2018107112, 2018.
   Google Scholar
• Hergenrother PJ, Riley AP Topoisomerase inhibitors with antibacterial and anticancer activity. PCT Int. Appl. WO 2018237140, 2018.
   Google Scholar
• Huang H-S, Yu D-S, Chen T-C Thiochromeno(2,3-c)quinolin-12-one derivatives, preparation method and application thereof. Can. Pat. Appl. CA 2866502, 2016.
   Google Scholar
• Huang H-S, Yu D-S, Chen T-C Thiochromeno[2,3-c]quinolin-12-one derivatives and their use as topoisomerase inhibitors. Eur. Pat. Appl. EP 3002287, 2016.
   Google Scholar
• Liu Y 10-Hydroxycamptothecin derivative, synthesis method and application thereof. Faming Zhuanli Shenqing CN 106588946, 2017.
   Google Scholar
• Huang Y, Wu A, Zhang Y Synthetic method of topoisomerase I inhibitor. Faming Zhuanli Shenqing CN 106674106, 2017.
   Google Scholar
• Cho WJ, Min SY, Le TN, et al. Synthesis of new 3-arylisoquinolinamines: effect on topoisomerase I inhibition and cytotoxicity. Bioorg Med Chem Lett. 2003;13:4451–4454.
   PubMed Web of Science ®Google Scholar
• Cho WJ Preparation of diarylisoquinolones and diarylisoquinolines as topoisomerase inhibitors Repub. Korean Kongkae Taeho Kongbo KR 2017049742, 2017.
   Google Scholar
• Cushman MS, Pommier YG Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors. U.S. Pat. Appl. Publ. US 20160318946, 2016.
   Google Scholar
• Shapiro SL, Geiger K, Youlus J, et al. Indandiones A modified Dieckman reaction. J Org Chem. 1961;26:3580–3582.
   Web of Science ®Google Scholar
• Cushman MS, Morrell AE, Nagarajan PY N-substituted indenoisoquinolines and synthesis thereof. U.S. Pat. Appl. Publ. US 8053443, 2011.
   Google Scholar
• Cushman MS, Lv P Prodrugs of anticancer agents indotecan and indimitecan. PCT Int. Appl. WO 2017136616, 2017.
   Google Scholar
• Cushman MS, Beck DE N-substituted indenoisoquinolines and synthesis thereof. U.S. Pat. Appl. Publ. US 9796753, 2017.
   Google Scholar
• Cushman MS, Beck DE, Pommier Y Aza-a-ring indenoisoquinolines as topoisomerase I poisons. PCT Int. Appl. WO 2017160898, 2017.
   Google Scholar
• Cushman MS, Wang P, Pommier Y, et al. Azaindenoisoquinoline compounds and uses thereof. PCT Int. Appl. WO 2018118852, 2018.
   Google Scholar
• Pan C, Kong S, Su G, et al. 2-(ω-Dialkylamino)aminoalkyl-3-(aryl-fused azolyl)quinoxaline compound as inhibiting topoisomerase I inhibitor useful in treatment of cancer and its preparation. Faming Zhuanli Shenqing. CN 108467392A, 2018.
   Google Scholar
• Wu L, Zhang C A kind of β lapachols list star element heterozygote and preparation method thereof and medical usage. Faming Zhuanli Shenqing CN 105461641, 2016.
   Google Scholar
• Wu L, Zhang C, Chao S O-Naphthoquinone derivative as topoisomerase I inhibitor and its preparation, pharmaceutical compositions and use in the treatment of cancer. Faming Zhuanli Shenqing CN 105541872, 2016.
   Google Scholar
• Sheng C, Zhang W, Dong G, et al. Preparation method of 10-hydroxyevodiamine anti-tumor compound and its application in preparation of anticancer drugs and topoisomerase inhibitor. Faming Zhuanli Shenqing CN 105418610, 2016.
   Google Scholar
• Sheng C, Dong G, Huang Y, et al. Rutaecarpin derivative and its preparation method and application with multiple target point antitumor activity. Faming Zhuanli Shenqing CN 108794474, 2018.
   Google Scholar
• Dong G, Sheng C, Chen S, et al. Rutaecarpin derivative of multiple target point anti-tumor activity and the preparation method and application thereof. Faming Zhuanli Shenqing CN 110066281, 2019.
   Google Scholar
• Epstein S, Zhang B, He S, et al. Preparation method of 4-methylamino acridine-N-phenylbenzamide as antitumor agents. Faming Zhuanli Shenqing CN 110407747, 2019.
   Google Scholar
• Zhang B, He S, Wang N, et al. N-o-substituted phenyl benzamide 4-methylamino acridine compound and preparation method and application thereof. Faming Zhuanli Shenqing CN 111057004, 2020.
   Google Scholar
• Song W, Wan M, Li S, et al. Phenanthridine derivative useful in treatment of cancer and its preparation. Faming Zhuanli Shenqing CN 108727397, 2018.
   Google Scholar
• An LK, Zhang X, Wang H, et al. Oxynitidine derivatives useful as inhibitors of topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1). PCT Int. Appl.WO 2020023700, 2020.
   Google Scholar
• Zhang X-R, Wang H-W, Tang W-L, et al. Discovery, synthesis, and evaluation of oxynitidine derivatives as dual inhibitors of DNA topoisomerase IB (TOP1) and tyrosyl-DNA phosphodiesterase 1 (TDP1), and potential antitumor agents. J Med Chem. 2018;61:9908–9930.
   PubMed Web of Science ®Google Scholar
• Clement B, Meier C, Steinhauer TN Novel pyrido-phenanthroline derivatives, production and use thereof as medicaments. Eur. Pat. Appl. EP 3330270; PCT Int. Appl. WO 2018099814, 2018.
   Google Scholar
• Pan C, Su G, Kong S, et al. Naphtho[1,2-h][1,6]naphthyridin-3(4H)-one compounds as topoisomerase I inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. Faming Zhuanli Shenqing CN 106243103, 2016.
   Google Scholar
• Zou H, Cai Y, Zhu H Preparing method and application of tetrahydro-angustine derivative including three R substituents. CN 107936021A, 2018.
   Google Scholar
• Zou H, Cai Y, Zhu H Preparation of (S)-tetrahydrogenangustine derivative as antitumor drug. CN 107827888A, 2018.
   Google Scholar
• Kim JS, Shin WS, Han JY Tumor targeting phototherapeutic agent and method for manufacturing thereof. Repub. Korea KR 1750658, 2017.
   Google Scholar
• Uesugi M, Di M, Kawase E Preparation of 6-amino-9-phenyl-3H-xanthen-3-imine and 9-phenyl-3-oxo-3H-xanthen-6-ol derivatives as selective fluorescent probes for removing human pluripotent stem cells. PCT Int. Appl. WO 2018043567, 2018.
   Google Scholar
• Mohan MA Compositions and methods for the treatment of cancer. PCT Int. Appl. WO 2016203352, 2016.
   Google Scholar
• Kan P, Hung C, Hong K, et al. Pharmaceutical compositions of hydrophobic camptothecin derivatives. U.S. Pat. Appl. Publ. US 20190321356, 2019.
   Google Scholar
• Santi DV, Fontaine S Synergistic cancer treatment. PCT Int. Appl. WO 2019140271, 2019.
   Google Scholar
• Kuo DM Pharmaceutical composition containing topoisomerase inhibitor and antimetabolite for decreasing side effects of pancreatic cancer drug, and its preparation method. Taiwan. TW I634901, 2018.
   Google Scholar
• Park JS, Jang MS, Oh WG Method for enhancing anticancer efficacy of DNA topoisomerase 1 inhibitor by using autophagocytosis regulating mechanism of methylenebis and related compounds. Repub. Korean Kongkae Taeho Kongbo KR 2019054423, 2019.
   Google Scholar
• Camacho KM, Menegatti S, Kumar S, et al. Polymer-drug conjugates for combination anticancer therapy. PCT Int. Appl. WO 2016145096A1, 2016.
   Google Scholar
• Friedman P, Eliasof S, Senderowicz A, et al. Treatment of cancer. PCT I nt. Appl. WO 2018102769A1, 2018.
   Google Scholar
• Pan D, Geng B Graphene base for targeting DNA major groove and inhibiting topoisomerase as well as preparation method and application thereof. Faming Zhuanli Shenqing CN 110917212A, 2020.
   Google Scholar
• Nandi A, Ghosh C, Basu S. Polymer conjugated graphene-oxide nanoparticles impair nuclear DNA and Topoisomerase I in cancer. Nanoscale Adv. 2019;4965.
   Web of Science ®Google Scholar
• Wang X, Yan X. Analyte-driven self-assembly of graphene oxide sheets onto hydroxycamptothecin-functionalized upconversion nanoparticles for the determination of type I topoisomerases in cell extracts. Anal Bioanal Chem. 2018;410:6761–6769.
   PubMed Web of Science ®Google Scholar
• Zuccaro L, Tesauro C, Kurkina T, et al. Real-time label-free direct electronic monitoring of topoisomerase enzyme binding kinetics on graphene. ACS Nano. 2015;9:11166–11176.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Govindan SV Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting trop-2. PCT Int. Appl. WO 2018156634A1, 2018.
   Google Scholar
• Goldenberg DM, Govindan SV Therapy of small-cell lung cancer with a topoisomerase-I inhibiting antibody-drug conjugate targeting Trop-2. U.S. Pat. Appl. Publ. US 20180185351A1, 2018.
   Google Scholar
• Hwu P, McKenzie JA, Mbofung RN, et al. Combination of topoisomerase-I inhibitors with immunotherapy in the treatment of cancer. PCT Int. Appl. WO 2017049199A1, 2017.
   Google Scholar
• Harki DA, Kaufmann SH, Perkins-Harki AL Methods and materials for assessing enzyme-nucleic acid complexes. U.S. Pat. Appl. Publ. US 20170003289A1, 2017.
   Google Scholar
• Bacha JA, Brown DM, Steinoe A, et al. Use of dianhydrogalactitol or analogs and derivatives in combination with a p53 modulator or a PARP inhibitor. PCT Int. Appl. WO 2018160758A1, 2018.
   Google Scholar
• Blanchette SF, Drummond DC, Fitzgerald JB, et al. Combination therapy for cancer treatment. PCT Int. Appl. WO 2017031445A1, 2017.
   Google Scholar
• Blanchette SF, Drummond DC, Fitzgerald JB, et al. Combination therapy using liposomal irinotecan and a PARP inhibitor for cancer treatment. PCT Int. Appl. WO 2017031442A1, 2017.
   Google Scholar
• Curley M, Louis CU Combination of an erbb3 inhibitor, topoisomerase I inhibitor, and an alkylating agent to treat cancer. PCT Int. Appl. WO 2018045256A1, 2018.
   Google Scholar
• Brake RL, Kannan K, Xu Q Combination therapy including a RAF inhibitor for the treatment of colorectal cancer. PCT Int. Appl. WO 2017066664A1, 2017.
   Google Scholar
• Strum JC, Bisi JE, Roberts PJ, et al. Treatment of Rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors. PCT Int. Appl. WO 2016040848A1, 2016.
   Google Scholar
• Chen L, Wang K, Qin G Method for predicting homologous recombination deletion mechanism and response of patient to cancer therapies. Faming Zhuanli Shenqing CN 107287285A, 2017.
   Google Scholar
• Bruenner NA, Stenvang J, Budinska E, et al. Companion diagnostics for colorectal cancer. PCT Int. Appl.WO 2019068755A1, 2019.
   Google Scholar
• Kobayashi Y, Watanabe N, Kurihara H, et al. Biomarker for camptothecin analog sensitivity as antitumor agent. Jpn. Kokai Tokkyo Koho JP 2016169945A, 2016.
   Google Scholar
• Hergenrother PJ, Riley AP Topoisomerase inhibitors with antibacterial and anticancer activity. PCT Int. Appl. WO 2018237140A1, 2018.
   Google Scholar
• Tse-Dinh Y-C SD Bacterial topoisomerase I inhibitors with antibacterial activity. U.S. Pat. Appl. Publ. US 20180079757A1, 2018.
   Google Scholar
• Y-C T-D, Giulianotti MA, Houghten R Bacterial topoisomerase inhibitors and use thereof. U.S. Pat. Appl. Publ. US 20170298004A1, 2017.
   Google Scholar
• Yang Z, Jiang T, Zhong H, et al. Inhibitor of bacterial type I topoisomerase and application. Faming Zhuanli Shenqing CN 106086023B, 2016.
   Google Scholar
• Nagaraja V, Ekins S, Godbole AA Treating mycobacterium tuberculosis infection with topoisomerase I inhibitors. Indian Pat. Appl. IN 2015CH00652, 2016.
   Google Scholar